Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The purpose of this study was to compare the clinical efficacy and safety of post-treatment nursing intervention (NI) with routine nursing care (RC) of patients with cardiovascular disease (CVD).

Methods: PubMed, EMBASE, the Cochrane Library, the China National Knowledge database, and other databases were used to comprehensively evaluate post-treatment NI versus RC for patients with CVD. Review Manager 5.0 was used to assess the impact of the results in the selected articles. Forest map analysis, sensitivity analysis, and bias analysis were performed on the collected data.

Results: In total, eight studies met the inclusion criteria. The systolic blood pressure in the RC group was higher than that in the NI group (MD =-3.72, 95% CI: -4.64 to -2.80, P<0.00001, I2=92%). The diastolic blood pressure in the NI group was lower than that in the RC group (MD =-5.36, 95% CI: -6.55 to -4.16, P<0.00001, I2=96%). There was a significant difference in fasting blood glucose levels between the NI group and the RC group (MD =-5.00, 95% CI: -9.47 to -0.52, P=0.03, I2=88%). The total cholesterol in the NI group was lower than that in the RC group (MD =-9.99, 95% CI: -14.52 to -5.45, P<0.0001, I2=85%). The triglyceride value of the NI group was lower than that of the RC group, with significant heterogeneity (MD =-24.24, 95% CI: -26.25 to -22.23, P<0.0001, I2=96%). A sensitivity analysis and funnel plot indicated that the study was reliable and publication bias was limited.

Discussion: The results showed that the efficacy and safety of NI were superior to RC after treatment of CVD. NI is worth popularizing.

Download full-text PDF

Source
http://dx.doi.org/10.21037/apm-21-2189DOI Listing

Publication Analysis

Top Keywords

patients cardiovascular
8
cardiovascular disease
8
systematic review
4
review meta-analysis
4
meta-analysis lifestyle
4
lifestyle nursing
4
nursing interventions
4
interventions patients
4
disease background
4
background purpose
4

Similar Publications

Background: Lower extremity arterial disease is a prevalent vascular condition leading to ischemic symptoms and increased risk of cardiovascular events. Drug-eluting stents have improved outcomes by reducing restenosis, with sirolimus emerging as a promising alternative to paclitaxel due to its safer profile. This study evaluates the efficacy and safety of novel polymer-free Amphilimus formulation (Sirolimus + fatty acid) eluting self-expanding stent in the treatment of femoropopliteal disease in a real-world population.

View Article and Find Full Text PDF

Importance: Patients with kidney failure (KF) receiving long-term dialysis have increased incidence of atrial fibrillation (AF). Patients with KF and AF have increased risk of stroke, death, and bleeding compared with age-matched cohorts. In KF, the use of oral anticoagulants (OACs) increases hemorrhage risk, offsetting potential benefits and making left atrial appendage occlusion (LAAO) a potentially promising solution for risk reduction in AF.

View Article and Find Full Text PDF

Introduction: Epigenetic changes are important modulators of gene expression. The histone acetyltransferase gene non-derepressible 5 (Gcn5) is emerging as a pivotal epigenetic player in metabolism and cancer, yet its role in obesity and cardiovascular disease remains elusive.

Aims: To investigate Gcn5 role in obesity-related endothelial dysfunction.

View Article and Find Full Text PDF

Portopulmonary hypertension (POPH), a subtype of pulmonary arterial hypertension (PAH), develops with portal hypertension and may persist after liver transplantation. While there have been successes using balloon-occluded retrograde transvenous obliteration (BRTO) for POPH, no reports exist on long-term follow-up. A 60-year-old man with hepatitis C cirrhosis developed POPH.

View Article and Find Full Text PDF

Introduction: This study examines the characteristics of adults with type 2 diabetes (T2D) who were not initially treated with an antihyperglycemic agent (AHA).

Methods: The analyses used Optum de-identified Market Clarity data from January 2013 through September 2023. The US study included nonpregnant adults with T2D who were continuously insured from 1 year prior through 5 years post diagnosis and did not fill a prescription for an AHA in the year after their initial T2D diagnosis.

View Article and Find Full Text PDF